Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

BACKGROUND: Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse. Two large phase III trials have shown significantly improved response rates (RR) of lenalidomide/dexamethasone compared with placebo/dexamethasone in relapsed MM (RMM) patients. These results have l...

Full description

Saved in:
Bibliographic Details
Published in:BMC Cancer
Main Authors: Baertsch, Marc-Andrea, Schlenzka, Jana, Mai, Elias K., Merz, Maximilian, Hillengaß, Jens, Raab, Marc S., Hose, Dirk, Wuchter, Patrick, Ho, Anthony D., Jauch, Anna, Hielscher, Thomas, Kunz, Christina, Luntz, Steffen, Klein, Stefan, Schmidt-Wolf, Ingo G. H., Goerner, Martin, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Salwender, Hans, Scheid, Christof, Nogai, Axel, Haenel, Mathias, Lindemann, Hans W., Martin, Hans, Noppeney, Richard, Weisel, Katja, Goldschmidt, Hartmut
Format: Artigo
Language:Inglês
Published: BioMed Central 2016
Subjects:
Study Protocol
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4845347/
https://ncbi.nlm.nih.gov/pubmed/27114074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2321-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items